AMGN logo

Amgen Inc.

AMGN
Healthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38
Next Earnings Report
Feb 2, 2027
EPS est. $5.65 · Revenue est. $10.45B
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Feb 19, 2026 (424B2). Possible dilution.

Upcoming Data Readouts (51)

Dec 2026
Est. completion
P1NF1
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Dec 2026
Est. completion
P1P2Acute Lymphoblastic Leukemia
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Jan 2027
Est. completion
P1P2Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Jan 2027
Est. completion
P1Healthy Participants
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
Jan 2027
Est. completion
P3Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Feb 2027
Est. completion
Heart Failure NYHA Class II
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
Mar 2027
Est. completion
Multiple Myeloma
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
Mar 2027
Est. completion
P1Healthy Participants
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
May 2027
Est. completion
P2Multiple Myeloma
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Jun 2027
Est. completion
NACardiovascular Risk
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
Jun 2027
Est. completion
P3Secondary Hyperparathyroidism
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Jun 2027
Est. completion
P3Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Jul 2027
Est. completion
NACrohn Disease (CD)
TIDHI Mental Health in IBD Patients Study
Jul 2027
Est. completion
P3Vasculitis
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Aug 2027
Est. completion
P3Obesity
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Aug 2027
Est. completion
P2Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Sep 2027
Est. completion
P2Cancer
The Drug Rediscovery Protocol (DRUP Trial)
Sep 2027
Est. completion
P2Metastatic Gastro-esophageal Adenocarcinoma
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
Sep 2027
Est. completion
P3Small Cell Lung Cancer
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Dec 2027
Est. completion
P3Obesity
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Awaiting Results (10)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P1
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
NCT07160257
Oct 2026
P2
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522
Jun 2026
P1P2
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Jun 2026
P2
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
NCT03500445
May 2026
P2
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
NCT06660810
May 2026
P4
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
NCT04951856
Dec 2025
P3
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619
Sep 2023
P2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299
Feb 2023
P1P2
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
NCT04599062
Jul 2018
P2
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
NCT02415413

SEC Filings (48)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 202610-QQuarterly reportDocumentIndex
Nov 3, 20268-KMaterial eventDocumentIndex
Oct 27, 20268-KMaterial eventDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jul 31, 20268-KMaterial eventDocumentIndex
Jun 11, 202611-KDocumentIndex
Jun 11, 202611-KDocumentIndex
May 20, 20268-KMaterial eventDocumentIndex
May 19, 20268-KMaterial eventDocumentIndex
May 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 22, 20268-KMaterial eventDocumentIndex
Apr 21, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 15, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 7, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 7, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 31, 2026ARSAnnual report to holdersDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 24, 202625-NSEDocumentIndex
Feb 19, 20268-KMaterial eventDocumentIndex
Feb 19, 2026424B2Offering prospectusDocumentIndex
Feb 17, 2026FWPDocumentIndex
Feb 17, 2026424B3Offering prospectusDocumentIndex
Feb 13, 2026S-3ASRShelf registrationDocumentIndex
Feb 13, 202610-KAnnual reportDocumentIndex
Feb 3, 20268-KMaterial eventDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 4, 20258-KMaterial eventDocumentIndex
Sep 8, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 6, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex
Jun 12, 202511-KDocumentIndex
Jun 12, 202511-KDocumentIndex
May 27, 20258-KMaterial eventDocumentIndex
May 2, 202510-QQuarterly reportDocumentIndex
May 1, 20258-KMaterial eventDocumentIndex
Apr 29, 2025DEFA14AProxy / shareholder voteDocumentIndex